Q3 2019 13F Holders as of 9/30/2019
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
96M
-
Number of holders
-
158
-
Total 13F shares, excl. options
-
55.7M
-
Shares change
-
-753K
-
Total reported value, excl. options
-
$2.38B
-
Value change
-
-$47.5M
-
Put/Call ratio
-
2.2
-
Number of buys
-
91
-
Number of sells
-
-63
-
Price
-
$42.78
Significant Holders of Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) as of Q3 2019
187 filings reported holding RARE - Ultragenyx Pharmaceutical Inc. - COMMON STOCK as of Q3 2019.
Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) has 158 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 55.7M shares
of 96M outstanding shares and own 58.05% of the company stock.
Largest 10 shareholders include Capital Research Global Investors (6.36M shares), Capital International Investors (6.01M shares), VANGUARD GROUP INC (5.07M shares), BlackRock Inc. (4.63M shares), PRICE T ROWE ASSOCIATES INC /MD/ (4.46M shares), WELLINGTON MANAGEMENT GROUP LLP (3.26M shares), Capital World Investors (2.37M shares), STATE STREET CORP (2.11M shares), FMR LLC (2.08M shares), and ALKEON CAPITAL MANAGEMENT LLC (1.59M shares).
This table shows the top 158 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.